miR‑888 regulates cancer progression by targeting multiple targets in lung adenocarcinoma

  • Authors:
    • Ji‑Xiang Cao
  • View Affiliations

  • Published online on: April 16, 2019     https://doi.org/10.3892/or.2019.7118
  • Pages: 3367-3376
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Aberrantly expressed miRNAs play a crucial role in the progression of lung adenocarcinoma. However, to date, the role of miR‑888 in lung adenocarcinoma progression is unclear. In the present study, the biological function of miR‑888 and its underlying mechanism in lung adenocarcinoma progression were explored. RT‑qPCR was performed to detect the expression of miR‑888 in 38 matched lung adenocarcinoma samples respectively. Next, the effects of miR‑888 on the proliferation, invasion and migration of lung adenocarcinoma A549 cells were evaluated by a series of gain‑ and loss‑of‑function assays. Our results revealed that miR‑888 was significantly upregulated in lung adenocarcinoma tissues, and its expression was markedly associated with clinical staging in patients. Moreover, ectopic expression of miR‑888 in vitro was revealed to function as a double‑edged sword in the progression of lung adenocarcinoma A549 cells by targeting multiple targets. Overexpression of miR‑888 promoted the invasion and migration of lung adenocarcinoma A549 cells by targeting E‑cadherin and tissue inhibitor of metalloproteinase 2. In addition, ectopic expression of miR‑888 inhibited the proliferation of lung adenocarcinoma A549 cells by targeting cell division cycle 7 (CDC7). In addition, the immunohistochemical results and The Cancer Genome Atlas (TCGA) database revealed that CDC7 was significantly upregulated in lung adenocarcinoma tissues, suggesting that miR‑888 may function as an oncogene in the progression of lung adenocarcinoma patients, and the miR‑888/CDC7 axis was not the dominant pathway for CDC7 regulation in patients with lung adenocarcinoma. In conclusion, our findings indicated that miR‑888 may act as a potential new therapeutic target for patients with lung adenocarcinoma.

References

1 

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI

3 

Torre LA, Siegel RL, Ward EM and Jemal A: Global cancer incidence and mortality rates and trends-An update. Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI

6 

Hwang HW and Mendell JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI

7 

Uddin A and Chakraborty S: Role of miRNAs in lung cancer. J Cell Physiol. 2018. View Article : Google Scholar

8 

Ma YS, Yu F, Zhong XM, Lu GX, Cong XL, Xue SB, Xie WT, Hou LK, Pang LJ, Wu W, et al: miR-30 family reduction maintains self-renewal and promotes tumorigenesis in NSCLC-initiating cells by targeting oncogene TM4SF1. Mol Ther. 26:2751–2765. 2018. View Article : Google Scholar : PubMed/NCBI

9 

Song Q, Ji Q, Xiao J, Wang L, Chen Y, Xu Y and Jiao S: miR-409 inhibits human non-small-cell lung cancer progression by directly targeting SPIN1. Mol Ther Nucleic Acids. 13:154–163. 2018. View Article : Google Scholar : PubMed/NCBI

10 

Hovey AM, Devor EJ, Breheny PJ, Mott SL, Dai D, Thiel KW and Leslie KK: miR-888: A novel cancer-testis antigen that targets the progesterone receptor in endometrial cancer. transl Oncol. 8:85–96. 2015. View Article : Google Scholar : PubMed/NCBI

11 

Gao SJ, Chen L, Lu W, Zhang L, Wang L and Zhu HH: miR-888 functions as an oncogene and predicts poor prognosis in colorectal cancer. Oncol Lett. 15:9101–9109. 2018.PubMed/NCBI

12 

Bobowicz M, Skrzypski M, Czapiewski P, Marczyk M, Maciejewska A, Jankowski M, Szulgo-Paczkowska A, Zegarski W, Pawłowski R, Polańska J, et al: Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer. Clin Exp Metastasis. 33:765–773. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Lewis H, Lance R, Troyer D, Beydoun H, Hadley M, Orians J, Benzine T, Madric K, Semmes OJ, Drake R, et al: miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. Cell Cycle. 13:227–239. 2014. View Article : Google Scholar : PubMed/NCBI

14 

Huang S and Chen L: MiR-888 regulates side population properties and cancer metastasis in breast cancer cells. Biochem Biophys Res Commun. 450:1234–1240. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Huang S, Cai M, Zheng Y, Zhou L, Wang Q and Chen L: miR-888 in MCF-7 side population sphere cells directly targets E-cadherin. J Genet Genomics. 41:35–42. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Hasegawa T, Glavich GJ, Pahuski M, Short A, Semmes OJ, Yang L, Galkin V, Drake R and Esquela-Kerscher A: Characterization and evidence of the miR-888 cluster as a novel cancer network in prostate. Mol Cancer Res. 16:669–681. 2018. View Article : Google Scholar : PubMed/NCBI

17 

Wang L, Liu Q, Lin D and Lai M: CD44v6 down-regulation is an independent prognostic factor for poor outcome of colorectal carcinoma. Int J Clin Exp Patho. 8:14283–14293. 2015.

18 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

19 

Bonte D, Lindvall C, Liu H, Dykema K, Furge K and Weinreich M: Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. Neoplasia. 10:920–931. 2008. View Article : Google Scholar : PubMed/NCBI

20 

Li Q, Xie W, Wang N, Li C and Wang M: CDC7-dependent transcriptional regulation of RAD54L is essential for tumorigenicity and radio-resistance of glioblastoma. Transl Oncol. 11:300–306. 2018. View Article : Google Scholar : PubMed/NCBI

21 

Sasi NK, Bhutkar A, Lanning NJ, MacKeigan JP and Weinreich M: DDK promotes tumor chemoresistance and survival via multiple pathways. Neoplasia. 19:439–450. 2017. View Article : Google Scholar : PubMed/NCBI

22 

Del Vescovo V, Grasso M, Barbareschi M and Denti MA: MicroRNAs as lung cancer biomarkers. World J Clin Oncol. 5:604–620. 2014. View Article : Google Scholar : PubMed/NCBI

23 

Chen C, Xue S, Zhang J, Chen W, Gong D, Zheng J, Ma J, Xue W, Chen Y, Zhai W, et al: DNA-methylation-mediated repression of miR-766-3p promotes cell proliferation via targeting SF2 expression in renal cell carcinoma. Int J Cancer. 141:1867–1878. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Yang C, Ma X, Guan G, Liu H, Yang Y, Niu Q, Wu Z, Jiang Y, Bian C, Zang Y and Zhuang L: MicroRNA-766 promotes cancer progression by targeting NR3C2 in hepatocellular carcinoma. FASEB J. 33:1456–1467. 2019. View Article : Google Scholar : PubMed/NCBI

25 

Masai H and Arai K: Cdc7 kinase complex: A key regulator in the initiation of DNA replication. J Cell Physiol. 190:287–296. 2002. View Article : Google Scholar : PubMed/NCBI

26 

Labib K: How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells? Genes Dev. 24:1208–1219. 2010. View Article : Google Scholar : PubMed/NCBI

27 

Datta A, Ghatak D, Das S, Banerjee T, Paul A, Butti R, Gorain M, Ghuwalewala S, Roychowdhury A, Alam SK, et al: p53 gain-of-function mutations increase Cdc7-dependent replication initiation. EMBO Rep. 18:2030–2050. 2017. View Article : Google Scholar : PubMed/NCBI

28 

Erbayraktar Z, Alural B, Erbayraktar RS and Erkan EP: Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness. Cancer Cell Int. 16:882016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 41 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Cao, J. (2019). miR‑888 regulates cancer progression by targeting multiple targets in lung adenocarcinoma. Oncology Reports, 41, 3367-3376. https://doi.org/10.3892/or.2019.7118
MLA
Cao, J."miR‑888 regulates cancer progression by targeting multiple targets in lung adenocarcinoma". Oncology Reports 41.6 (2019): 3367-3376.
Chicago
Cao, J."miR‑888 regulates cancer progression by targeting multiple targets in lung adenocarcinoma". Oncology Reports 41, no. 6 (2019): 3367-3376. https://doi.org/10.3892/or.2019.7118